Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial Academic Article uri icon

Overview

MeSH Major

  • Myelodysplastic Syndromes

abstract

  • Astex Pharmaceuticals and Stand Up To Cancer.

publication date

  • June 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/S2352-3026(19)30029-8

PubMed ID

  • 31060979

Additional Document Info

start page

  • e317

end page

  • e327

volume

  • 6

number

  • 6